Comparison
While PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101, Setmelanotide is approved for chronic weight management in patients with POMC, PCSK1, LEPR deficiencies and Bardet–Biedl syndrome by reducing hunger and promoting weight loss92.
While PT-141 works as the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101, Setmelanotide is a potent synthetic melanocortin-4 receptor (MC4R) agonist derived from a POMC/α-MSH–related sequence that restores downstream MC4R signaling in genetic obesity syndromes3192100.
PT-141 is 7 amino acids long, whereas Setmelanotide is shorter as it has a length of amino acids. PT-141 is made up of a sequence of sequence data not available in the current dataset. Setmelanotide is made up of a sequence of sequence data not available in the current dataset.
PT-141
POMC
Setmelanotide
POMC
No related articles are linked to these peptides yet.